|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Merozoite surface protein-1 (MSP-1), a major asexual blood stage antigen, and circumsporozoite protein (CSP), a component of sporozoites that includes a Plasmodium vivax B-cell epitope, are strong candidates for use in a malaria vaccine.
|
21907198 |
2011 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although immunity against MSP1 alone will not confer protection against malaria, demonstrating a relative and sustained increase in T-cell immunity to MSP1 after vaccination would be a reasonable measurement of vaccine responsiveness.
|
20696832 |
2010 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allelic diversity in the merozoite surface protein-1 (MSP-1) of Plasmodium falciparum, a major malaria vaccine candidate, was examined in clinical isolates from holoendemic northern Tanzania.
|
9920333 |
1998 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The blood-stage malaria vaccines were administered alone, or together (MSP1+AMA1), or with a pre-erythrocytic malaria vaccine candidate (MSP1+ME-TRAP).
|
23089736 |
2012 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The merozoite surface protein 1 (MSP-1) gene of Plasmodium falciparum encodes a major immune target under development as a malaria vaccine.
|
16291768 |
2005 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).
|
16437602 |
2005 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Severity of malaria was not linked to the predominance of any particular msp1 or msp2 allelic types, independent of methods used for genotyping.
|
23408340 |
2013 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
|
16291762 |
2005 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasmodium falciparum merozoite surface protein-1 (MSP1) has been extensively studied as a blood-stage malaria vaccine candidate, with most work focused on the conserved 19 kDa and semi-conserved 42 kDa C-terminal regions (blocks 16-17) and the hypervariable N-terminal repeat region (block 2).
|
20070906 |
2010 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Samples were analysed using bead-based multiplex assays for IgG antibodies for six Plasmodium antigens: four human malaria species-specific merozoite surface protein-1 19kD antigens (MSP-1) and Apical Membrane Antigen-1 (AMA-1) for Plasmodium falciparum and Plasmodium vivax.
|
31331340 |
2019 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, Gambian children who had been vaccinated with SPf66 and who were parasitaemic at the end of the first malaria transmission season after vaccination had significantly fewer detectable P. falciparum genotypes than control children, as determined by polymerase chain reaction analysis of 3 polymorphic loci--the msp1 block 2 repeat region, the msp2 repeat region, and the R11 region of the glutamate-rich protein gene (glurp).
|
10450429 |
1999 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein we investigate the frequency of recombination-driven allelic diversity and temporal variation of msp1 in Rufiji, eastern coastal Tanzania, where malaria transmission is intense.
|
17556608 |
2007 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic characterization of the P. falciparum isolate obtained by analysis of msp1 and msp2 amplicons revealed the coexistence of two genotypes causing the first malaria episode and the presence of a unique isolate responsible for the recurrence.
|
15528762 |
2004 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fragment size in the Block 2 repetitive region of merozoite surface protein 1 (MSP1) has commonly been used as a molecular marker in studies of malaria transmission dynamics and host immunity in Plasmodium falciparum malaria.
|
16517218 |
2006 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
A significant increase in antibodies against Plasmodium falciparum antigens AMA1, MSP2, NANP and Plasmodium vivax antigen MSP1 in individuals with past history of malaria were observed when compared to those who did not.
|
22905743 |
2012 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have developed an experimental vaccine candidate (PyCMP) based on pre-erythrocytic (CSP) and erythrocytic (MSP1) stage antigens derived from the rodent malaria parasite P. yoelii.
|
28483199 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the work presented here, the relationship between antibody specificity and the infecting parasite genotype was investigated in asymptomatic subjects and patients with uncomplicated malaria in order to possibly clarify the relationship between anti-MSP1 block2 antibodies and clinical malaria.
|
11755430 |
2002 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we suggest a potential regulatory role of the HLA-DRB1 alleles in the production of antibodies to a conserved region of P. vivax CSP and MSP1 in Brazilian population exposed to malaria.
|
22107686 |
2012 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Thalassaemia trait is associated with antibody prevalence against malaria antigens AMA-1 and MSP-1.
|
25604491 |
2015 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The multiplicities of infection (MOI) were low and comparable for msp-1 (1.19 vs 1.22) and msp-2 (1.11 vs 1.10), respectively between malaria and arbovirus-malaria groups.
|
26969623 |
2016 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
|
24303947 |
2014 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 200 kDa merozoite surface protein 1 (MSP-1) of malaria parasites, a strong vaccine candidate, plays a key role during erythrocyte invasion and is a target of host protective immune response.
|
20167126 |
2010 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fine specificity of neonatal lymphocytes to an abundant malaria blood-stage antigen: epitope mapping of Plasmodium falciparum MSP1(33).
|
18292564 |
2008 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings may be useful for the development of a malaria vaccine based on Plasmodium falciparum MSP-1(42).
|
16377036 |
2006 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that MSP-1, especially the partially conserved subunit MSP-1<sub>83</sub>, is a major target of opsonizing antibodies acquired during natural exposure to malaria.
|
28877929 |
2017 |